Next 10 |
2025-02-17 08:15:00 ET Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector. Depending on the ETF, investors may be able to track up-and-coming...
2025-02-12 22:47:17 ET More on AtriCure AtriCure, Inc. (ATRC) Q4 2024 Earnings Call Transcript AtriCure GAAP EPS of -$0.33 misses by $0.09, revenue of $124.28M beats by $2.44M AtriCure reports preliminary results for fourth quarter Seeking Alpha’s Quan...
2025-02-12 22:46:43 ET AtriCure, Inc. (ATRC) Q4 2024 Earnings Conference Call February 12, 2025, 04:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer ...
2025-02-12 16:03:03 ET More on AtriCure AtriCure reports preliminary results for fourth quarter Seeking Alpha’s Quant Rating on AtriCure Historical earnings data for AtriCure Financial information for AtriCure Read the full article on Seeking...
Fourth Quarter 2024 Worldwide revenue of $124.3 million – an increase of 16.6% year over year Full Year 2024 Worldwide revenue of $465.3 million – an increase of 16.5% year over year Launched cryoSPHERE ® +, cryoSPHERE MAX ™ and AtriClip ® FLEX-M...
Citius Pharmaceuticals Inc. (CTXR) is expected to report $-1.25 for Q1 2025 Casio Computer Co Ltd ADR (CSIOY) is expected to report for Q3 2025 Dundee Precious Metals Inc. (DPMLF) is expected to report $0.45 for Q4 2024 Elite Pharmaceuticals, Inc. (ELTP) is expected to report for Q3 2...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2024 financial results ...
2025-01-13 13:43:44 ET More on AtriCure AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript AtriCure Non-GAAP EPS of -$0.17 beats by $0.03, revenue of $115.91M beats by $3.66M Seeking Alpha’s Quant Rating on AtriCure Historical earnings data for Atr...
AtriCure, Inc. (Nasdaq: ATRC) , a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2024 and pro...
2025-01-03 00:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
2025-02-17 08:15:00 ET Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector. Depending on the ETF, investors may be able to track up-and-coming...
Fourth Quarter 2024 Worldwide revenue of $124.3 million – an increase of 16.6% year over year Full Year 2024 Worldwide revenue of $465.3 million – an increase of 16.5% year over year Launched cryoSPHERE ® +, cryoSPHERE MAX ™ and AtriClip ® FLEX-M...
Citius Pharmaceuticals Inc. (CTXR) is expected to report $-1.25 for Q1 2025 Casio Computer Co Ltd ADR (CSIOY) is expected to report for Q3 2025 Dundee Precious Metals Inc. (DPMLF) is expected to report $0.45 for Q4 2024 Elite Pharmaceuticals, Inc. (ELTP) is expected to report for Q3 2...